Trimodal Therapy For Muscle Invasive Bladder Cancer



frontiers | Frontiers in Surgery

TYPE Review
PUBLISHED 07 December 2023
DOI 10.3389/fsurg.2023.1276746

Check for updates

OPEN ACCESS

EDITED BY
Chunguang Yang,
Huazhong University of Science and Technology, China

REVIEWED BY
Aisha Siebert,
Northwestern Medicine, United States
Francesco Claps,
The Netherlands Cancer Institute (NKI), Netherlands

*CORRESPONDENCE
Ahmad Al-Qudimat
aalqudimat@hamad.qa

RECEIVED 12 August 2023
ACCEPTED 16 October 2023
PUBLISHED 07 December 2023

CITATION
Al-Qudimat AR, Singh K, Ojha LK, Moustafa DA, Elaarag M, Al-Zoubi RM and Aboumarzouk OM (2023) Comparing trimodal therapy with radical cystectomy in muscle-invasive bladder cancer: an updated meta-analysis.
Front. Surg. 10:1276746.
doi: 10.3389/fsurg.2023.1276746

COPYRIGHT
© 2023 Al-Qudimat, Singh, Ojha, Moustafa, Elaarag, Al-Zoubi and Aboumarzouk. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Comparing trimodal therapy with radical cystectomy in muscle-invasive bladder cancer: an updated meta-analysis

Ahmad R. Al-Qudimat[1,2]*, Kalpana Singh[3], Laxmi K. Ojha[3], Diala Alhaj Moustafa[3], Mai Elaarag[3], Raed M. Al-Zoubi[3,4,5] and Omar M. Aboumarzouk[1,6]

[1]Surgical Research Section, Department of Surgery, Hamad Medical Corporation, Doha, Qatar, [2]Department of Public Health, College of Health Sciences, Qatar University, Doha, Qatar, [3]Department of Nursing Research, Hamad Medical Corporation, Doha, Qatar, [4]Department of Biomedical Sciences, College of Health Sciences, Qatar University, Doha, Qatar, [5]Department of Chemistry, College of Science, Jordan University of Science and Technology, Irbid, Jordan, [6]School of Medicine, Dentistry and Nursing, The University of Glasgow, Glasgow, United Kingdom

Background: We conducted this meta-analysis to compare the two muscle-invasive bladder cancer (MIBC) treatment modalities in terms of cancer-specific survival (CSS) and other outcome indicators.

Method: A systematic review and meta-analysis were performed in accordance with the Preferred Reporting Items for Systematic Reviews (PRISMA) guidelines. The search was conducted using various academic databases including Scopus, PubMed, Cochrane database, EMBASE, Chinese biomedical literature database, Wan fang databases, and China National Knowledge Internet databases between 1966 and December 2023. This review protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO) No. (*CRD42023398977*).

Result: This study included a total of 54,816 patients diagnosed with bladder cancer from 14 studies, of which 6,228 patients were assigned to the trimodal therapy (TMT) group and 48,588 patients were assigned to the radical cystectomy (RC) group. Based on the results, the RC group exhibited a higher rate of survival than the TMT group [pooled hazard ratio (HR) = 1.23, 95% CI: 1.18–1.28, $Z = 1.46$, $P < 0.001$]. In terms of CSS, patients in the RC group had a longer CSS compared with those in the TMT group (pooled HR = 1.47, 95% CI: 1.29–1.67, $Z = 5.893$, $P < 0.001$). Compared with RC, TMT is significantly associated with an increased risk of both types of mortality (pooled HR: 1.30, $P < 0.001$).

Conclusion: Overall, the findings of this meta-analysis suggest that RC treatment may be associated with improved overall survival. Moreover, it was observed that cancer-specific survival was significantly prolonged among patients in the RC group as opposed to those who received TMT. In addition, it was shown that patients who received TMT exhibited a higher risk of all-cause mortality when compared with those who underwent RC.

KEYWORDS

cancer, bladder preserving, radical cystectomy, muscle-invasive, trimodal

Abbreviations

TMT, trimodal therapy; RC, radical cystectomy; MIBC, muscle-invasive bladder cancer; OS, overall survival; CSS, cancer-specific survival; HR, hazard ratios; PRISMA, preferred reporting items for systematic reviews and meta-analyses; PROSPERO, prospective register of systematic reviews; RR, risk ratio; PC, partial cystectomy; CR, complete response; TUR, transurethral resection.

Trimodal therapy for muscle invasive bladder cancer has emerged as a compelling treatment strategy for patients diagnosed with this aggressive form of cancer. Muscle invasive bladder cancer (MIBC) is characterized by the tumor invading the muscularis propria of the bladder wall, presenting a significant challenge in terms of treatment and patient outcomes. Traditional approaches often include radical cystectomy or chemotherapy, but trimodal therapy offers a multifaceted approach that combines transurethral resection of the bladder tumor (TURBT), chemotherapy, and radiation therapy. This article delves into the components, benefits, challenges, and future directions of trimodal therapy for MIBC.

Understanding Muscle Invasive Bladder Cancer

Muscle invasive bladder cancer represents a critical stage of bladder cancer, where the cancer cells breach the superficial layers and infiltrate deeper into the bladder wall. Key facts about MIBC include:

- Prevalence: MIBC accounts for approximately 25% of newly diagnosed bladder cancer cases.
- Symptoms: Common symptoms include hematuria (blood in urine), urgency, frequency, and pelvic pain.
- Diagnosis: Diagnosis typically involves cystoscopy, imaging studies, and histopathological evaluation.

Due to its aggressive nature, MIBC necessitates prompt and effective treatment strategies to improve patient prognosis and quality of life.

Components of Trimodal Therapy

Trimodal therapy for MIBC consists of three primary components, each playing a crucial role in the overall treatment plan:

1. Transurethral Resection of the Bladder Tumor (TURBT)

TURBT is usually the first step in the trimodal approach. This procedure involves the surgical removal of the visible tumor from the bladder wall, allowing for both diagnosis and debulking of the tumor. Key objectives of TURBT include:

- Accurate Staging: Determining the extent of the cancer helps in formulating the subsequent treatment plan.
- Symptom Relief: Removing the tumor can alleviate symptoms such as obstruction or bleeding.
- Tumor Control: Reducing the tumor burden can improve the efficacy of subsequent therapies.

2. Chemotherapy

Following TURBT, systemic chemotherapy is administered to target any residual cancer cells and reduce the risk of recurrence. This often involves:

- Neoadjuvant Chemotherapy: Administered prior to radiation therapy, typically consisting of a combination of cisplatin and gemcitabine.
- Objectives: The primary aim is to shrink the tumor, making it more manageable for radiation treatment while also addressing micrometastatic disease.

3. Radiation Therapy

Radiation therapy is utilized after the chemotherapy regimen to target the bladder and surrounding tissues. Its role in trimodal therapy is critical for:

- Local Control: Delivering high doses of radiation to eradicate any remaining cancer cells in the bladder.
- Preservation of Bladder Function: In contrast to radical cystectomy, which removes the bladder entirely, radiation therapy aims to preserve bladder function, allowing for normal urinary processes.

Benefits of Trimodal Therapy

The integration of TURBT, chemotherapy, and radiation therapy into a single treatment protocol offers several benefits for patients with MIBC:

1. Preservation of Bladder

One of the most significant advantages of trimodal therapy is the potential to preserve the bladder. For many patients, avoidance of radical cystectomy is a priority, as it can lead to significant changes in lifestyle and bodily function.

2. Improved Survival Rates

Clinical studies have indicated that trimodal therapy may lead to comparable or even superior survival rates compared to radical cystectomy in select patient populations. The combination of treatments allows for a comprehensive approach to cancer management.

3. Enhanced Quality of Life

By preserving bladder function and minimizing the extent of surgical intervention, patients often experience a better quality of life post-treatment. Preserving urinary function and avoiding the complications associated with urinary diversion are key considerations for patients.

4. Tailored Treatment Approach

Trimodal therapy allows for a personalized treatment plan that can be adjusted based on individual patient characteristics, tumor biology, and response to therapy.

Challenges and Considerations

While trimodal therapy presents numerous advantages, there are also challenges and considerations that healthcare providers and patients must be aware of:

1. Patient Selection

Not all patients with MIBC are suitable candidates for trimodal therapy. Factors influencing candidacy include:

- Tumor Characteristics: The size, stage, and grade of the tumor can affect treatment decisions.
- Patient Health: The overall health and comorbidities of the patient must be considered, as chemotherapy and radiation can have significant side effects.

2. Side Effects and Complications

Each component of trimodal therapy carries potential side effects, including:

- Chemotherapy: Nausea, vomiting, fatigue, immunosuppression, and potential renal toxicity.
- Radiation Therapy: Acute side effects such as cystitis (inflammation of the bladder), diarrhea, and fatigue; long-term effects may include bladder fibrosis or secondary malignancies.

3. Treatment Adherence

Successful outcomes from trimodal therapy depend on patient adherence to the entire treatment regimen. Challenges such as transportation, financial burden, and psychological factors can impact adherence rates.

Future Directions and Research

As the field of oncology continues to evolve, research into trimodal therapy for MIBC is ongoing. Future directions may include:

1. Biomarkers for Personalization

Identifying biomarkers that predict response to chemotherapy and radiation may help tailor therapies for individual patients, optimizing outcomes while minimizing unnecessary side effects.

2. Novel Therapeutic Agents

Investigating new chemotherapeutic agents, targeted therapies, and immunotherapies could enhance the effectiveness of trimodal therapy and improve patient outcomes.

3. Long-term Follow-up Studies

Continued research into long-term outcomes of patients treated with trimodal therapy is essential to understand the durability of responses, late effects of treatment, and quality of life post-therapy.

Conclusion

Trimodal therapy for muscle invasive bladder cancer represents a promising approach that combines surgery, chemotherapy, and radiation to enhance patient outcomes while preserving bladder integrity. By understanding the components, benefits, and challenges of this treatment strategy, healthcare providers can better inform and support patients as they navigate their cancer journey. Ongoing research into optimizing and personalizing this approach will be crucial in the fight against MIBC, ultimately aiming to improve survival rates and quality of life for patients.

Frequently Asked Questions

What is trimodal therapy for muscle invasive bladder cancer?

Trimodal therapy is a treatment approach that combines three modalities: transurethral resection of the bladder tumor (TURBT), chemotherapy, and radiation therapy, aimed at preserving the bladder while controlling cancer.

How effective is trimodal therapy compared to radical cystectomy?

Studies suggest that trimodal therapy can achieve similar survival rates to radical cystectomy, especially in patients who are not surgical candidates or prefer bladder preservation.

Who are the ideal candidates for trimodal therapy?

Ideal candidates include patients with muscle invasive bladder cancer who have a solitary tumor, good performance status, and no evidence of metastatic disease, as well as those who wish to avoid radical cystectomy.

What types of chemotherapy are used in trimodal therapy?

Typically, a combination of cisplatin-based chemotherapy regimens is used, often administered before and after radiation therapy to enhance the effectiveness of the treatment.

What are the potential side effects of trimodal therapy?

Side effects can include urinary incontinence, bladder irritation, fatigue, gastrointestinal issues, and potential long-term effects on bladder function, depending on individual patient factors.

How long does the trimodal therapy treatment process usually take?

The trimodal therapy process typically spans several months, starting with TURBT, followed by chemotherapy cycles, and then a course of radiation therapy, which usually lasts about 5 to 6 weeks.

What is the role of follow-up care after trimodal therapy?

Follow-up care is crucial for monitoring for recurrence, managing side effects, and assessing bladder function, typically involving regular cystoscopies and imaging studies.

Can trimodal therapy be used for all stages of bladder cancer?

Trimodal therapy is primarily indicated for localized muscle invasive bladder cancer and is not recommended for metastatic disease or non-muscle invasive bladder cancer.

What advancements are being made in trimodal therapy for bladder cancer?

Recent advancements include the exploration of novel chemotherapy agents, immunotherapy options, and improved radiation techniques to enhance outcomes and minimize side effects.

Trimodal Therapy For Muscle Invasive Bladder Cancer

Chrome 다운로드 및 설치 **-** 컴퓨터 **- Google Chrome** 고객센터
Chrome 웹브라우저를 무료로 다운로드하여 설치하고 이를 사용하여 웹을 탐색할 수 있습니다. Chrome 설치 방법 중요: 다운로드하기 전에 현재 사용 중인 운영체제에서 Chrome이 지원되는지와 필요한 기타 시스템 요구사항을 확인할 수 있습니다.

Télécharger et installer Google Chrome
Installer Chrome Important : Avant de télécharger Chrome, vous pouvez vérifier s'il est compatible avec votre système d'exploitation et les autres configurations système requises.

Google Chrome herunterladen und installieren
Chrome installieren Wichtig: Bevor Sie es herunterladen, sollten Sie nachsehen, ob Ihr Betriebssystem von Chrome unterstützt wird und ob auch alle anderen Systemanforderungen erfüllt sind.

Scaricare e installare Google Chrome
Come installare Chrome Importante: prima di scaricare Chrome, puoi controllare se supporta il tuo sistema operativo e se soddisfa gli altri requisiti di sistema.

Google Chrome downloaden en installeren
Google Chrome downloaden en installeren Je kunt de Chrome-webbrowser kosteloos downloaden en installeren en deze gebruiken om op internet te browsen.

Ladda ned och installera Google Chrome - Dator - Google Chrome ...
Om du har problem med att installera Chrome på din Windows-dator kan du använda den alternativa länken för att ladda ned Chrome på en annan dator. Välj operativsystemet för enheten du vill installera Chrome på. Flytta filen till datorn där du vill installera Chrome.

Pobieranie i instalowanie Google Chrome
Jak zainstalować Chrome Ważne: zanim pobierzesz aplikację, sprawdź, czy Chrome obsługuje Twój system operacyjny i czy spełniasz wszystkie wymagania systemowe.

Are all 4K Blu Rays region free? : r/4kbluray - Reddit
Oct 27, 2021 · At the end of the day, there's probably 5 or less 4Ks that are out that are region locked, so it might be something to look for in the future. In general you're pretty safe …

Best Region Free Blu-Ray Players 2025 - Audiophiles
Jan 29, 2025 · Yes, a Region Free Blu-Ray Player is designed to play Blu-Ray discs from any region. However, the player’s compatibility with other disc formats like DVD or CD depends on …

Are 4K Blu-Ray Discs Region Locked? - SlashGear
Jun 29, 2025 · Going back to 4K UHD Blu-rays, you don't have to worry about this in the slightest. If you are happy using your region A-locked PS5 to play discs, you are free to get 4K discs …

Region-Free 4k UHD Blu-ray Players: Fact or Fiction?
May 31, 2016 · Are all 4K UHD Blu-ray Players Region-Free? No, and this is where the misconception and misinformation come into play. For some reason, manufacturers have …

Does region-free work in the US? - ExpertBeacon
May 14, 2024 · Yes, region-free DVD, Blu-ray, and 4K Blu-ray players and media work perfectly fine when used in the United States. Region-free refers to devices and discs that are not …

LG 4K Region Free Smart WiFi UHD 4K Ultra HD Blu-ray & DVD ...

Sep 26, 2019 · Region Free UHD player with HDR (High Dynamic Range), HDR10, & Dolby Vision. This player has built-in support for the highest-quality surround sound formats, like …

Blu-ray Region Codes: Are the Discs & Players Locked?
Nov 5, 2023 · 4K UHD Blu-ray discs do not have region coding; this only affects regular 1080p Blu-rays. You can’t buy a region-free Blu-ray player, but you can modify some models.

4K UHD Bluray Region Lock : r/4kbluray - Reddit
Jun 29, 2024 · Obviously it's annoying and even the Sony website it says the following regarding Bluray discs "Ultra HD Blu-ray Discs, on the other hand, are region-free and can be played …

region free 4k movies? - AVForums
Aug 4, 2019 · There is no region protection on any UHD disk from anywhere. This means that you can safely buy a 4K disk from anywhere and it will work in a UK player. Same is not true for …

Are there region-free 4K Blu-ray players? | Top Ten Reviews
Mar 28, 2023 · Not only does it offer full region-free capabilities for Blu-Ray (both UHD and standard), DVDs, and CDs, but it’ll also offer 3D playback, Dolby Vision support, and built-in …

Back to Home